
In the age of Ozempic, is there still a role for weight-loss surgery?
For the first time, health care providers have a combination of highly effective therapies to offer patients with obesity, a condition that has long been one of the most difficult to treat. The outlook is especially exciting for patients who are severely overweight — including those who are considered too heavy for surgery.
Indeed, there may exist a future where drugs and other interventions prevent people from ever becoming obese and needing weight-loss surgery. But that future is far off, say surgeons and other weight-loss experts.
In fact, even as millions of Americans are now taking drugs that dramatically improve weight loss, surgeons say their tool may be more powerful than ever.
'A massive amount of people have tried these medications, so the question becomes: 'How well do they work and is there a role for bariatric surgery in the era of these drugs?'' said Dr. Jonathan Carter, a UCSF surgeon who specializes in minimally invasive procedures.
Bariatric surgery has for decades been the most effective and durable weight-loss tool available. The specific procedures vary, but the most common operation now is the gastric sleeve surgery, in which a large portion of the stomach is removed. Roughly a quarter of a million Americans undergo a bariatric procedure each year.
The surgeries are highly effective for weight loss — patients can lose about a third of their body weight within two years, and they generally keep off most of those pounds long-term. The side effects with the sleeve procedure are minimal and may include gas, bloating and nutritional deficiencies that can be alleviated with diet.
Meanwhile, more than 1 in 10 Americans have now taken the newest weight-loss medications. On these drugs, patients can lose about 15% of their weight, but they must remain on the drugs for life — those who stop gain all of the weight back. Side effects are similar to the surgery.
The drugs and the surgery work somewhat similarly by essentially quashing people's hunger and cravings. And though the surgery is more expensive at the outset — about $12,000 to $15,000 — it's cheaper in the long-term compared to drugs that cost about $1,000 a month. Both treatments are often, but not always, covered by insurance.
With the surgery, 'You take someone who is 100 pounds overweight and their knees hurt and they have sleep apnea,' said Carter, 'and you do a one-hour intervention and a year later they've lost 100 pounds and their knees don't hurt and the sleep apnea is gone. It's like a butterfly coming out of a cocoon.'
But bariatric surgery has never been a popular weight-loss option for those who need it most. Of all Americans who are eligible for surgery, only about 1% undergo the procedure. Surgeons and weight-loss experts say that's largely been due to misconceptions about the procedure and stigma around obesity.
'If you've been treating patients with obesity for decades, you always felt like, 'Yes, I have a great treatment, I can do these surgeries and do them safely, I believe in them whole-heartedly,'' said Dr. Dan Azagury, a Stanford University bariatric surgeon. 'But you were still limited in your capacity to treat patients.'
Azagury took over Stanford's Lifestyle and Weight Management Center in February 2020, about a year before Ozempic, the first blockbuster weight-loss drug, blew up. Over the next 18 months, the number of patients on weight-loss medications jumped from 50 to 2,000.
He said friends would often ask him if he would be out of a job soon. The drugs, though, have in some ways validated the surgical interventions, Azagury said.
Weight loss has notoriously been a fraught topic in doctors offices, with patients feeling judged and doctors feeling frustrated by their lack of treatment options. 'A lot of times doctors would just say that you should eat less,' Azagury said.
'And I think patients intrinsically didn't see obesity as a medical condition,' he said.
The success of recent weight-loss drugs, though, has made that conversation more palatable both to patients and providers, Azagury said. And he believes that is making some patients more amenable to a surgical option.
There are, broadly, now three buckets for treating weight loss: diet and exercise, medication and surgery. The first option is likely best for people who don't have a lot of weight to lose and who are not facing any immediate complications related to their weight. They can manage their own treatment, or get a referral to a community or private weight-loss program.
From there, patients with more serious obesity can decide if medication or surgery — or both — is the best option for them. Some people may be resistant to the idea of any surgical procedure and opt for medication. Others may decide that they would rather not deal with weekly injections for the rest of their life and prefer a one-time operation.
Many patients, though, will end up with multiple interventions over their lifetime. They may start with medication and eventually decide they want a more permanent solution. Or they may get bariatric surgery and a few years later decide to start a medication if their weight is creeping back up.
Mandy Hinz, 47, fought with her weight all her life, and it's only in the past two years that she finally felt like she had options. She had inquired about bariatric surgery about 20 years ago but was told she would need to lose 100 pounds before doctors would consider it safe. After that, she was up and down, peaking at about 415 pounds on her 5-foot, 3-inch frame.
She started Ozempic in early 2023, and though the drug made her feel 'super sick,' she stuck with it and lost about 30 pounds. Around that time, Hinz, a Sacramento resident, was referred to the bariatric program at UCSF, and in October 2023, she finally got a gastric sleeve. She got down to about 200 pounds from the surgery, then started a different weight-loss drug and lost another 20 pounds.
Though she's still obese for her height, Hinz said she's not interested in losing much more weight. 'I'm 180 and completely happy,' Hinz said. 'My journey has been absolutely amazing.'
She noted that even with all of the tools at her disposal, losing the weight was never easy. And she has friends for whom even the newest therapies aren't solving all of their weight issues. But for Hinz, the weight-loss drugs finally unlocked a path that had never felt accessible to her.
'Being big my whole life, I missed out on a lot of stuff,' she said. Walking up and down stairs had become difficult, or spending a day on her feet at an amusement park. 'Now I can run up and down the stairs, I can walk around the amusement park the whole day. I went on my first hike a year and a half ago. It's like, let's go, let's do this.'
Azagury said he's most thrilled for the patients — and their doctors — who have the most weight to lose, and especially those for whom a combination of medical and surgical therapies could be life-saving.
'The worst thing for a bariatric surgeon is when you get a patient in your clinic and it's too late — their condition is so bad that surgery is unsafe,' Azagury said. 'The conversation is, 'You have a condition I can treat, but I can't treat you.' It's the worst conversation. And I never have to have it anymore. Now I can tell them: 'I can't do surgery, but I have a good alternative for you.''

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Mom, 58, Used a 'Miracle' GLP to 'Be Thin' for Her Son's Wedding. She Claims It Made Her So Sick She Almost Missed the Big Day
NEED TO KNOW Ali Eastburn, a 58-year-old mom from Nashville, was struggling with losing weight after menopause She turned to the GLP-1 medication Ozempic because she wanted 'to be thin' for her son's upcoming wedding, but when her weight loss stalled, she said she increased her Ozempic dose — after which her appendix burst A rep for the manufacturer told PEOPLE, "Novo Nordisk remains confident in the benefit-risk profile of our GLP-1 medicines, when used consistent with their indications and product labeling"A mom who started taking Ozempic to drop weight before her son's wedding nearly missed the big day after her appendix burst. She claimed the medical emergency was caused by the medication, which she said 'almost killed me.' Ali Eastburn, 58, struggled with her 'post-menopausal' weight for years. 'My whole metabolism just changed and I had tried everything to lose weight,' the Nashville mom said, according to the Daily Mail. Eastburn, who was a size 16 before starting Ozempic, worried about how she might look in the photos for her son Chase's upcoming wedding. In April, her doctor prescribed her the weight loss drug. Ozempic and others in its class (the active agent, semaglutide, is marketed under the brand names Wegovy and Mounjaro) impact satiety. While Ozempic is approved by the FDA for people with type 2 diabetes and not formally approved for weight loss, it has become a trendy way to shed extra pounds. A Novo Nordisk spokesperson told PEOPLE: "Semaglutide has been extensively examined in robust clinical development programs, large real-world-evidence studies and has cumulatively over 33 million patient years of exposure." They continued, "Semaglutide's efficacy and safety have been extensively demonstrated in people with obesity/overweight with robust evidence for improving health outcomes. Semaglutide has demonstrated improvements in CV death, stroke and myocardial infarction. Novo Nordisk remains confident in the benefit-risk profile of our GLP-1 medicines, when used consistent with their indications and product labeling." Eastburn said, "At first, it seemed like a miracle. The weight was just coming off.' By the start of July, Eastburn had lost 15 lbs. 'I felt better and that there was hope,' she said. But then, her weight loss stalled: 'I knew I had to do something drastic as I was desperate to look better. I didn't want to hate the wedding photos for the rest of my life,' Eastburn said. 'I upped my dose so I could get to my goal of losing 20 lbs.' Eastburn did not clarify whether she consulted with a doctor before increasing her dosage of Ozempic. The FDA warned in 2024 that taking more than the recommended dose of compounded semaglutide could lead to "gastrointestinal effects (e.g., nausea, vomiting, abdominal pain)," as well as "fainting, headache, migraine, dehydration, acute pancreatitis and gallstones." After upping her dose, Eastburn said she felt an immediate impact. 'The first week the nausea was uncontrollable and I had no desire to eat or drink anything,' she said, explaining she felt an 'all-new level' of 'excruciatingly painful' heartburn. Explaining she was 'sick as a dog,' Eastburn said she was dry heaving and fighting the urge to vomit when she went shopping for a dress to wear to the wedding. She said she ended up in the emergency room twice, struggling with nausea and 'violent diarrhea.' Still, she flew from Nashville to Orange County, Calif., on July 15 for the wedding — only to get so ill on the flight that once they landed, 'an ambulance took me to the hospital straight away and I was diagnosed with a burst appendix.' A burst appendix is a medical emergency, according to the Cleveland Clinic, and happens when the appendix becomes inflamed; When it bursts, it sends bacteria throughout your body, risking life-threatening complications. Eastburn spent four days in the hospital, missing Chase's rehearsal dinner. 'I just cried as I felt like it was my fault as I did this to myself. I missed all of this as I wanted to be thin and it broke my heart,' said Eastburn, who nearly missed the wedding. 'We went at the very last minute as I was in so much pain. Sitting on a chair was so painful and I could barely walk. When my son saw me sitting in the front row, he came over and hugged me for the longest time and bawled like a baby,' she said. 'We didn't think I was going to be at the wedding, much less live to tell anyone about it. I didn't care about my size as I was just so proud to be there. It was hard to stand and do the mother-son dance, but I was so grateful,' she said, sharing that while 'I was so swollen and my stomach was so puffy,' her weight 'was the last thing on my mind.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Eastburn claimed the medication caused her health struggle; There have been sporadic case studies that suggest appendicitis could be a potential risk, but there has been no direct link established between the medication and the condition. 'I will never jeopardize or endanger myself again with any drugs to lose weight as that was too close of a call,' Eastburn said. 'I would say think long and hard before taking a GLP-1 as it almost killed me," she claimed. "If you care about your family or people that you love, think about them having to live life without you as it might kill you. Being thin is not worth losing your life.' Read the original article on People
Yahoo
4 hours ago
- Yahoo
Mom, 58, Used a 'Miracle' GLP to 'Be Thin' for Her Son's Wedding. She Claims It Made Her So Sick She Almost Missed the Big Day
NEED TO KNOW Ali Eastburn, a 58-year-old mom from Nashville, was struggling with losing weight after menopause She turned to the GLP-1 medication Ozempic because she wanted 'to be thin' for her son's upcoming wedding, but when her weight loss stalled, she said she increased her Ozempic dose — after which her appendix burst A rep for the manufacturer told PEOPLE, "Novo Nordisk remains confident in the benefit-risk profile of our GLP-1 medicines, when used consistent with their indications and product labeling"A mom who started taking Ozempic to drop weight before her son's wedding nearly missed the big day after her appendix burst. She claimed the medical emergency was caused by the medication, which she said 'almost killed me.' Ali Eastburn, 58, struggled with her 'post-menopausal' weight for years. 'My whole metabolism just changed and I had tried everything to lose weight,' the Nashville mom said, according to the Daily Mail. Eastburn, who was a size 16 before starting Ozempic, worried about how she might look in the photos for her son Chase's upcoming wedding. In April, her doctor prescribed her the weight loss drug. Ozempic and others in its class (the active agent, semaglutide, is marketed under the brand names Wegovy and Mounjaro) impact satiety. While Ozempic is approved by the FDA for people with type 2 diabetes and not formally approved for weight loss, it has become a trendy way to shed extra pounds. A Novo Nordisk spokesperson told PEOPLE: "Semaglutide has been extensively examined in robust clinical development programs, large real-world-evidence studies and has cumulatively over 33 million patient years of exposure." They continued, "Semaglutide's efficacy and safety have been extensively demonstrated in people with obesity/overweight with robust evidence for improving health outcomes. Semaglutide has demonstrated improvements in CV death, stroke and myocardial infarction. Novo Nordisk remains confident in the benefit-risk profile of our GLP-1 medicines, when used consistent with their indications and product labeling." Eastburn said, "At first, it seemed like a miracle. The weight was just coming off.' By the start of July, Eastburn had lost 15 lbs. 'I felt better and that there was hope,' she said. But then, her weight loss stalled: 'I knew I had to do something drastic as I was desperate to look better. I didn't want to hate the wedding photos for the rest of my life,' Eastburn said. 'I upped my dose so I could get to my goal of losing 20 lbs.' Eastburn did not clarify whether she consulted with a doctor before increasing her dosage of Ozempic. The FDA warned in 2024 that taking more than the recommended dose of compounded semaglutide could lead to "gastrointestinal effects (e.g., nausea, vomiting, abdominal pain)," as well as "fainting, headache, migraine, dehydration, acute pancreatitis and gallstones." After upping her dose, Eastburn said she felt an immediate impact. 'The first week the nausea was uncontrollable and I had no desire to eat or drink anything,' she said, explaining she felt an 'all-new level' of 'excruciatingly painful' heartburn. Explaining she was 'sick as a dog,' Eastburn said she was dry heaving and fighting the urge to vomit when she went shopping for a dress to wear to the wedding. She said she ended up in the emergency room twice, struggling with nausea and 'violent diarrhea.' Still, she flew from Nashville to Orange County, Calif., on July 15 for the wedding — only to get so ill on the flight that once they landed, 'an ambulance took me to the hospital straight away and I was diagnosed with a burst appendix.' A burst appendix is a medical emergency, according to the Cleveland Clinic, and happens when the appendix becomes inflamed; When it bursts, it sends bacteria throughout your body, risking life-threatening complications. Eastburn spent four days in the hospital, missing Chase's rehearsal dinner. 'I just cried as I felt like it was my fault as I did this to myself. I missed all of this as I wanted to be thin and it broke my heart,' said Eastburn, who nearly missed the wedding. 'We went at the very last minute as I was in so much pain. Sitting on a chair was so painful and I could barely walk. When my son saw me sitting in the front row, he came over and hugged me for the longest time and bawled like a baby,' she said. 'We didn't think I was going to be at the wedding, much less live to tell anyone about it. I didn't care about my size as I was just so proud to be there. It was hard to stand and do the mother-son dance, but I was so grateful,' she said, sharing that while 'I was so swollen and my stomach was so puffy,' her weight 'was the last thing on my mind.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Eastburn claimed the medication caused her health struggle; There have been sporadic case studies that suggest appendicitis could be a potential risk, but there has been no direct link established between the medication and the condition. 'I will never jeopardize or endanger myself again with any drugs to lose weight as that was too close of a call,' Eastburn said. 'I would say think long and hard before taking a GLP-1 as it almost killed me," she claimed. "If you care about your family or people that you love, think about them having to live life without you as it might kill you. Being thin is not worth losing your life.' Read the original article on People


CNBC
5 hours ago
- CNBC
Healthy Returns: Medicare, Medicaid will reportedly pilot covering obesity drugs – a potential win for drugmakers
For once, the Trump administration may be giving some drugmakers a reason to celebrate. The Trump administration is planning to experiment with covering costly weight loss drugs under Medicare and Medicaid, the Washington Post reported on Friday. That plan could expand access to millions of Americans with obesity who can't currently afford Novo Nordisk's Wegovy and Eli Lilly's Zepbound, blockbuster GLP-1 drugs that cost around $1,000 per month before insurance. In a statement to CNBC about the plan, the Department of Health and Human Services said all drug coverages undergo a "cost-benefit review." The Centers for Medicare and Medicaid Services "does not comment on potential models or coverage," the department added. The reported plan – if it ultimately takes effect – would be a huge win for Eli Lilly, Novo Nordisk and many Americans. Spotty insurance coverage of obesity drugs remains the biggest barrier to access for patients – and it's choking broader uptake and revenue growth for the two pharmaceutical giants. Many health plans, including Medicare, cover GLP-1s for treatment of diabetes, but not obesity. Medicaid coverage of obesity drugs is limited and varies by state, according to health policy research organization KFF. But it's important to remember that this plan isn't exactly new. In November, the Biden administration proposed having Medicare and Medicaid cover obesity treatments, which would have extended access to roughly 3.4 million Medicare beneficiaries and about 4 million Medicaid recipients. The proposal was controversial at the time, as it would cost taxpayers as much as $35 billion over the next decade, a congressional analysis found. The Trump administration dropped that proposal in April, but said it could reconsider coverage of those drugs in the future. Let's get into what the newest reported iteration of the plan looks like. Under the Trump administration's reported pilot plan, state Medicaid programs and Medicare Part D plans would be able to voluntarily choose to cover Ozempic, Wegovy, Mounjaro and Zepbound for patients for "weight management" purposes. That's according to several Centers for Medicare and Medicaid Services documents obtained by the Post. The plan is expected to start in April 2026 for Medicaid and January 2027 for Medicare plans, the Post reported. It's unclear how exactly the plan will play out, Jared Holz, Mizuho health care equity strategist, said in a note to clients on Friday. Holz said he expects the government to put some coverage parameters in place related to factors like age, body weight, body mass index and other comorbidities, or coexisting chronic health conditions. He also said the pricing of the drugs will be a "major consideration." Holz said he expects the government to pay less than the current list prices of drugs. But having that coverage would expand access and could help drive higher sales volumes, he noted. Another factor to consider is how much the government is willing to crack down on so-called compounding pharmacies, which are allowed in rare cases to sell cheaper, unapproved versions of GLP-1s. The pharmaceutical industry fiercely opposes those knock-off GLP-1s, as their safety and efficacy aren't vetted by regulators and they are, in some cases, illegally sold at scale. Holz said the industry's complaints to the government about compounded GLP-1s have so far "not been met with a widespread shut-down." But overall, Holz said the Trump administration's reported willingness to consider covering obesity drugs is "a slight positive as far as industry sentiment." It's definitely a breath of fresh air for Eli Lilly, Novo Nordisk and other drugmakers – including Amgen, Roche, AstraZeneca and Pfizer – that are hoping to bring their own obesity drugs to market. The last six months have been anything but smooth for the broader industry: The Trump administration has ratcheted up calls for drugmakers to lower U.S. drug prices, overhauled federal health agencies and could impose sweeping tariffs on pharmaceuticals imported into the country any day now. We'll keep watching to see whether this plan gets implemented, so stay tuned for our coverage! Feel free to send any tips, suggestions, story ideas and data to Annika at After reporting its second straight earnings miss and guidance cut, UnitedHealth Group completed its executive sweep by replacing CFO John Rex. Executives on the earnings call admitted to mis-execution in Medicare Advantage and pledged to get back to profitability and win back investor trust. Nearly two years ago it was CVS Health under pressure, after profits in the company's Aetna health insurance division were torpedoed by low Medicare Advantage Star quality ratings. This week, CVS beat and raised its outlook on the strength of its MA program. CEO David Joyner, now one year into the job, told me he feels good about the turnaround at Aetna and its Medicare business. On top of that, the company saw market share gains in its stores, thanks in part to winning over Rite Aid customers. Humana, similarly, has seen progress on its turnaround, but CFO Celeste Mellet told me that all insurers are grappling with pricing plans for next year amid high medical costs. One big cost driver right now, Mellet told CNBC, is oncology drugs, as some expensive therapies are now being used in combination. The next moment of truth for the Medicare Advantage players will come over the next six weeks – when they'll learn the fate of their Star ratings for 2026 plans. Long-time health-care executive Dr. Marc Harrison has stepped down as CEO of General Catalyst's Health Assurance Transformation Company, or HATCo, and has moved into a strategic advisor role, CNBC has confirmed. The venture capital firm brought in Harrison and announced the formation of HATCo in 2023. In a release at the time, General Catalyst said the company would work closely with health system partners, and that it would eventually acquire and operate its own health system. Months later, HATCo announced its plans to buy Summa Health, a nonprofit integrated health system in northeast Ohio. Under its new structure, Summa would become a for-profit organization, and General Catalyst said it would introduce new tech-enabled solutions that aim to make care more accessible and affordable. Buying a health system is an unprecedented move in the venture industry, and the deal wasn't well received by some members of the Ohio community. Hundreds signed a petition urging Summa to remain a nonprofit and to halt negotiations with HATCo. Ohio Attorney General Dave Yost conditionally approved the deal in June, though he outlined a number of "enforceable commitments" as part of the agreement. HATCo will have to notify the Attorney General of transactions that could trigger antitrust concerns for 10 years after the deal closes, for instance. Harrison went to medical school in the late 1980s and has spent most of his career within health systems, most recently as CEO of Intermountain Healthcare. General Catalyst told CNBC that Harrison will continue to provide the firm's CEO, Hemant Taneja, with clinical insights and will remain connected to its ecosystem in his new role. "It became increasingly clear to both Marc and to us that Marc's role would best be accomplished as a strategic advisor to Hemant Taneja as we bring that ambition and vision to life," a General Catalyst spokesperson said. Daryl Tol, the head of General Catalyst's Health Assurance Ecosystem, was promoted to president of HATCo, the spokesperson said. He will spearhead the firm's day-to-day- work with Summa Health leadership. General Catalyst has also appointed Kate Walsh, the former Massachusetts Secretary of Health and Human Services, to HATCo's board. In addition, she will serve as the chair of the board at Summa Health once the transaction closes. "We are grateful for Marc's leadership and collaboration as co-founder and CEO to help get us to this point in the evolution of HATCo, and we look forward to leveraging his invaluable perspective as we continue to progress," the spokesperson said.